Shares of PolyPid Ltd. (PYPD) are up 8% in pre-market, as the company makes progress with its lead program D-PLEX100.
D-PLEX100, PolyPid's lead product candidate, is designed to prevent surgical site infection (SSIs) using the company's PLEX local drug-delivery platform. The FDA has scheduled a face-to-face pre-NDA meeting, a key near-term catalyst for the program.
PolyPid is advancing toward a New Drug Application submission for D-PLEX100 in early 2026, following positive Phase 3 results and recent alignment with the U.S. FDA. The company also completed a successful IMOH GMP inspection, supporting its readiness for commercial manufacturing.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.